Consensus Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.01 ^USD	-8.10%		-9.08%	+2.21%

Feb. 27	North American Morning Briefing : Stock Futures -2-	DJ
Feb. 26	Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	MT

Evolution of the average Target Price on Cogent Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1b947613634888ff0a.UaJoIMOH6m0kB0ioj0LKjTdl7hyuRHZZY5YUUf7bnqA.YPcYaa7Jjw9ncX_n1RCIylUshlLhDCILId5yCc6v6NAowCtIlcvHInZfPw~fea574a27f4a6d3ad1d3c3f438b00381

Analyst Recommendations on Cogent Biosciences, Inc.

Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	Feb. 26	MT
Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14	Feb. 26	MT
Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating	Feb. 23	MT
Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target	Feb. 08	MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating	Dec. 15	MT
Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20	Dec. 11	MT
JPMorgan Chase Starts Coverage on Cogent Biosciences with Overweight Rating, $18 Price Target	Dec. 08	MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $27 From $28, Keeps Buy Rating	23-06-08	MT
Baird Initiates Cogent Biosciences at Outperform With $20 Price Target	23-04-28	MT
Needham Adjusts Price Target on Cogent Biosciences to $23 From $24, Keeps Buy Rating	23-03-15	MT
Wedbush Adjusts Price Target on Cogent Biosciences to $20 From $19, Maintains Outperform Rating	23-03-14	MT
SVB Securities Adjusts Price Target on Cogent Biosciences to $20 From $18, Maintains Outperform Rating	23-01-05	MT
Needham Starts Cogent Biosciences With Buy Rating, Price Target is $24	22-12-14	MT
Guggenheim Adjusts Price Target on Cogent Biosciences to $24 From $22, Maintains Buy Rating	22-12-13	MT
Cogent Biosciences Says Bezuclastinib Shows Overall Response Rate of 73% in Advanced Systemic Mastocytosis Phase 2 Trial	22-12-12	MT
Wedbush Trims Cogent Biosciences' Price Target to $19 From $20, Keeps Outperform Rating	22-11-14	MT
Guggenheim Adjusts Cogent Biosciences Price Target to $22 From $18, Maintains Buy Rating	22-08-18	MT
Wedbush Adjusts Cogent Biosciences Price Target to $20 From $17, Maintains Outperform Rating	22-08-09	MT
SVB Financial Adjusts Cogent Biosciences Price Target to $20 From $15, Maintains Outperform Rating	22-08-08	MT
Guggenheim Starts Cogent Biosciences at Buy With $15 Price Target	22-06-28	MT
SVB Securities Adjusts Cogent Biosciences' Price Target to $15 from $14, Keeps Outperform Rating	22-06-13	MT
Wedbush Adjusts Price Target for Cogent Biosciences to $17 From $21, Maintains Outperform Rating	22-05-10	MT
Wedbush Adjusts Cogent Biosciences' Price Target to $21 From $19; Outperform Rating Kept	22-03-15	MT
COGENT BIOSCIENCES : HC Wainwright Starts Cogent Biosciences at Buy With $25 Price Target	21-10-11	MT
COGENT BIOSCIENCES : Wedbush Adjusts Cogent Biosciences PT to $19 From $24, Maintains Outperform Rating	21-08-16	MT